Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
作者： Frank A. Sinicrope , Qian Shi , Fabienne Hermitte , Erica N Heying , Al Bowen Benson
DOI: 10.1200/JCO.2018.36.4_SUPPL.614
关键词: Risk category 、 Oncology 、 Internal medicine 、 Colorectal cancer 、 Adjuvant 、 FOLFOX 、 Stage (cooking) 、 Colon carcinoma 、 Medicine
摘要: 614Background: A consensus interpretation of the IDEA colon cancer study results suggested that risk categories based on T/N stage grouping be used to guide decision-making for duration (3 vs 6 mon...
sci-hub.st 参考文章(0)